Principal Investigator
Dr. Geno MarcoviciPhD, DABAAHP
Dr. Geno Marcovici is the founder and principal investigator of Continuum Innovative, LLC. Across more than thirty years of sustained scientific inquiry, his work has consistently bridged rigorous academic investigation with real-world translational application.
His earliest published contribution — the first randomized, double-blind, placebo-controlled trial to demonstrate efficacy of a botanically derived 5-alpha-reductase inhibitor in androgenetic alopecia (2002) — established a methodological and mechanistic foundation that subsequent investigators have built upon for more than two decades. Work conducted in active collaboration with the State University of New York's Center for Functional Genomics extended this thesis into the molecular domain by demonstrating measurable suppression of LPS-activated inflammatory gene expression in human keratinocytes.
A pivotal 2016 University of Chicago program then asked a more fundamental question: at the level of the androgen axis itself, how does Marcovici’s investigational composition compare with the pharmaceutical standard of care? Using parallel hair-follicle dermal-papilla and LNCaP prostate assays, the defined multi-component botanical composition down-regulated androgen-pathway biomarkers and, on the measured endpoints, outperformed finasteride — establishing the molecular rationale that first presaged a state-of-the-art nano-delivery platform which subsequently led to Continuum’s novel, multi-faceted intellectual property armamentarium.
More recent investigation has integrated nanotechnology-enabled delivery — specifically β-cyclodextrin inclusion complexes — into clinically observable follicular response, culminating in the TrichoCyte™ formulation platform and its 2020 publication in Cosmetics (MDPI). That trajectory continues into the present. In 2025, in collaboration with CryoConcepts LP, Dr. Marcovici co-authored a first-in-field innovative-practice report in the Journal of Complementary Research and Alternative Medicine describing the use of a cryo-chilled, CO₂-bolstered delivery device to amplify the nano-botanical platform in advanced-stage androgenetic alopecia. Phenotypic reversal observed by day 90 was sufficient to terminate the planned 270-day protocol 180 days ahead of schedule — re-establishing the program at the leading edge of follicular regenerative medicine. The full arc — from hypothesis through molecular mechanism through clinical translation and now device-augmented amplification — defines the current scientific direction of Continuum Innovative.
Career & Leadership
- Beginning 1993Founder & Chief Scientific Officer (former)Advanced Restoration Technologies, Inc. (HairGenesis®) — former operating entity
Founded the research and development organization that developed the HairGenesis® brand — among the first botanically derived hair restoration platforms validated under formal randomized controlled trial conditions.
- 2019 — PresentPlatform Direction — TrichoCyte™TrichoCyte™ — proprietary product-line platform
Direction of the TrichoCyte™ β-cyclodextrin inclusion-complex platform — a nanotechnology-enabled topical delivery system for follicular bioactives.
- PresentFounder & Principal InvestigatorContinuum Innovative | Life Sciences Division
Hypothesis-driven research entity investigating biological stability — how it is maintained, lost, and restored — using the hair follicle as a uniquely accessible regenerative organ system.
Areas of Expertise
Dr. Marcovici's expertise extends well beyond any single mechanism-of-action. Below is the broader landscape — board credentialing, cross-disciplinary peer review, regenerative medicine, and translational formulation science — alongside the androgen-driven follicular biology for which his published program is best known.
Board Certification & Credentialing
- Board-certified in Regenerative Medicine — continuously credentialed for more than 11 years
- Doctoral training in biomedical sciences with formal post-doctoral research experience
- Decades of bench-to-bedside translational practice across multiple therapeutic areas
Peer Review — Cross-Disciplinary
- Invited manuscript reviewer for international journals across cardiology, pulmonology, dermatology, endocrinology, psychiatry, oncology, and complementary/integrative medicine
- Editorial board and ad-hoc reviewer roles spanning both basic-science and clinical literature
- Routine review of randomized controlled trial design, mechanistic in-vitro work, and translational case series
Regenerative & Translational Medicine
- Systems-biology approach to tissue stability — how it is maintained, lost, and restored
- Intracrine signaling, stem/progenitor biology, and the regenerative micro-environment
- Translational formulation science: concept → bench → clinic → worldwide commercialization
Hair Biology & Androgen-Driven Disease
- Androgenetic alopecia — pathogenesis, hormonal drivers, and rational therapeutic design
- 5α-reductase inhibition (synthetic and botanically derived) and androgen-receptor signaling
- Follicular inflammation, cytokine biology, and genomic profiling of inflammatory pathways
Drug Delivery & Formulation Innovation
- β-cyclodextrin inclusion complexes and nano-enabled topical delivery
- Concomitant oral + topical regimen design for follicular and systemic targets
- Device-augmented delivery — including cryo-carboxy amplification of botanical actives
Intellectual Property & Commercial Translation
- Inventor on multiple issued U.S. and international patents
- Formulation, clinical evaluation, regulatory positioning, and global brand development
- Strategic and scientific advisor to industry partners and clinical practices
Landmark Program · 2016
The University of Chicago Research Program
The single most mechanistically decisive body of work in the program was conducted with collaborators at the University of Chicago. Where the earlier studies had established clinical effect and inflammatory involvement, the Chicago work asked the harder question: at the level of the androgen axis itself, what is the composition actually doing — and how does it compare with the pharmaceutical standard of care?
Using parallel, cell-based assay systems — human hair-follicle dermal-papilla cells alongside LNCaP androgen-responsive prostate cells — the investigators profiled a defined multi-component botanical composition (beta-sitosterol, thioctic acid, and carnitine) against androgen-pathway biomarkers in both tissues. The composition down-regulated those androgen markers, and on the measured endpoints it outperformed finasteride.
Follicular dermal papilla and prostate LNCaP assays run in parallel — androgen-axis effects demonstrated across two independent androgen-responsive tissues, not one.
Benchmarked directly against finasteride, the reference 5α-reductase inhibitor, rather than against placebo or vehicle alone.
The molecular rationale established here underwrote the subsequent nano-enabled β-cyclodextrin delivery work and the current intracrine and immune-privilege intellectual property.
Marcovici G, Li YC, Mouser G, Wang J, Chen L. Blockade of androgen markers using a novel betasitosterol, thioctic acid and carnitine-containing compound in prostate and hair follicle cell-based assays. Phytotherapy Research, 2016. PMID: 26990224.
Selected Peer-Reviewed Publications
A representative selection across the arc of investigation. A complete record — including review activity — is maintained on ORCID .
- 2002Prager N, Bickett K, French N, Marcovici G.A randomized, double-blind, placebo-controlled study to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia.J Altern Complement Med · PMID: 12006122
- 2011Chittur S, Parr B, Marcovici G.Inhibition of inflammatory gene expression in keratinocytes using a composition containing carnitine, thioctic acid, and Serenoa repens extract.Evid Based Complement Alternat Med (eCAM) · PMC3137880
- 2016Marcovici G, Li YC, Mouser G, Wang J, Chen L.Blockade of androgen markers using a novel betasitosterol, thioctic acid and carnitine-containing compound in prostate and hair follicle cell-based assays.Phytotherapy Research · University of Chicago collaboration · PMID: 26990224
- 2020Marcovici G, Bauman A.An uncontrolled case series using a botanically derived, β-cyclodextrin inclusion complex in two androgenetic-alopecia-affected male subjects.Cosmetics (MDPI) · DOI: 10.3390/cosmetics7030065
- 2025Niedbala S, Campbell E, Young L, Marcovici G.An uncontrolled innovative test of cryo-chilled carbon dioxide as a novel amplification of a nano-botanical multi-acting therapy in advanced-stage androgenetic alopecia.J Complement Res Altern Med 2(1):1–9 · First-in-field cryo-carboxy × nano-botanical platform
Education & Credentialing
- PhD — biomedical research training underpinning three decades of original investigation.
- DABAAHP — Diplomate, American Board of Anti-Aging Health Practitioners.
- Active peer reviewer for journals across Nature Portfolio, Springer, Elsevier, Wiley, and MDPI — with 100+ manuscripts reviewed across more than 50 medical sub-specialty journals.
Intellectual Property
- HairGenesis® — USPTO Reg. No. 3,567,177.
- Trichoceutical® — USPTO Reg. No. 3,935,889.
- TrichoCyte™ β-cyclodextrin inclusion-complex delivery platform — proprietary formulation system.
- Additional pending and issued IP covering hair restoration formulations and delivery technologies.
Active USPTO Provisional Filings
Provisional applications presently in force
- Progressive Autoimmune Loss of Privilege (USPTO 64/065,059) — Systems and methods for the preservation of follicular territorial integrity via restoration of immune privilege and suppression of ectopic antigen presentation.
- Intracrine Structure–Function Dynamics (USPTO 64/063,263) — Systems-architecture modulation of intracrine androgen metabolism and pleiotropic signaling within the hair-follicle micro-organ.
- Coordinated Multi-Nodal Stabilization (USPTO 64/069,570) — Coordinated multi-nodal stabilization of follicular phenotype architecture through integrated pleiotropic signaling modulation.
- Senescence Biology (USPTO 64/073,264) — Methods and compositions for preserving or restoring regenerative competence in senescent scalp hair follicles.
- Menopause-Associated Follicular Destabilization (USPTO 64/095,147) — Systems and methods addressing hormonally driven follicular destabilization in menopause-associated hair loss.
- Follicle–Stromal Field Biology / Spatially Organized Tissue-Field Regulation (USPTO Provisional 64/136,221; filed August 18, 2026; Filing #6) — the follicular–stromal field framework, also referred to internally as the Field Theory of AGA.
- Convergent Privilege Collapse (USPTO Provisional 64/156,448; filed September 16, 2026; Filing #7) — a unifying framework for multi-compartment loss of biological containment and the restoration of regenerative competence.
See the Intellectual Property page for full innovation themes and prosecution context.
Three decades of inquiry. One continuous body of work bridging discovery, mechanism, and translation.